HOME ASBESTOS DRUGS POLLUTANTS ACCIDENTS MALPRACTICE STORY OF OUR FIRM SEARCH

Mesothelioma Publication - Italian Mortality Rates

Predictions of mortality from pleural mesothelioma in Italy: Abstract of an article on mesothelioma and Italian mortality rates.

Epidemiology Unit, Occupational Medicine Department, National Institute for Occupational Safety and Prevention, Rome, Italy.

Italy was the second main asbestos producer in Europe, after the Soviet Union, until the end of the 1980s, and raw asbestos was imported on a large scale until 1992.

The Italian pattern of asbestos consumption lags on average about 10 years behind the United States, Australia, the United Kingdom and the Nordic countries. Measures to reduce exposure were introduced in the mid-1970s in some workplaces. In 1986, limitations were imposed on the use of crocidolite and in 1992 asbestos was definitively banned.

We have used primary pleural cancer mortality figures (1970-1999) to predict mortality from mesothelioma among Italian men in the next 30 years by age-cohort-period models and by a model based on asbestos consumption figures. The pleural cancer/mesothelioma ratio and mesothelioma misdiagnosis in the past were taken into account in the analysis. Estimated risks of birth cohorts born after 1945 decrease less quickly in Italy than in other Western countries.

The findings predict a peak with about 800 mesothelioma annual deaths in the period 2012-2024. Results estimated using age-period-cohort models were similar to those obtained from the asbestos consumption model. (c) 2004 Wiley-Liss, Inc.


PMID: 15645436 [PubMed - as supplied by publisher]

CONTACT WEITZ & LUXENBERG FOR A FREE LEGAL EVALUATION OF YOUR CASE

First Name
Last Name
Home Phone
Work Phone
City and State
Email
Were you diagnosed with Asbestosis? Yes
No
Were you diagnosed with lung cancer? Yes
No
Were you diagnosed with Mesothelioma? yes
no
What is your date of diagnosis?
Additional Comments
Best time to call?

For legal help anywhere in the U.S. call:

1 - 800 - 476 - 6070

Prior results do not guarantee a similar outcome.

ATTORNEY ADVERTISING

TABLE OF CONTENTS
Mesothelioma Mesothelioma Home Page
head Mesothelioma: An Overview
kleio The Clock Is Ticking
asbestos Our Toughest Cases
head Diagnosis
treatment Symptoms, Stages, Treatment
kleio Latest News
New York Numbers
Asbestos


IN THIS SECTION
Farnesyltransferase Inhibitors
Cancer Immunotherapy
Great Britain
Poland
Pemetrexed Therapy
Sv40 Specific Recall Immunity
Polish Cases
Extra Pleural Pneumonectomy
Intraoperative Radiation Therapy
Calretinin
Hyaluronan
Granulocyte Colony Stimulating Factor
Canada
Pemetrexed (Alimta)
Calretinin Antibodies
Greece
Neoplasia
FDA Pemetrexed
Secreted Frizzled Related Protein
Tumor Necrosis
Podoplanin
Lymphohistiocytoid
Pathogenesis of Malignant Pleural
Diagnostic Difficulties
Mesothelioma from Adenocarcinoma
Mesothelial Proliferation
ThinPrep Cytospin
Effusion
Chemotherapy Options
Heparanase
Malignant Deciduoid
Mortality
Pemetrexed in Malignant Pleural Mesothelioma
Pleural Mesothelioma
Prognostic Analysis
Italian Mortality Rates
Vinorelbine and Oxaliplatin
DNA Methylation Profiles
Primary Malignant Pericardial Mesothelioma
Abdominal CAT Scans
China
Disseminated Malignant
Statistical Validation
Pathogenesis
Lung Adenocarcinoma
Japan


RETURN BACK TO
Mesothelioma
Latest News
see also:

Calretinin Mesothelioma Publication speaks about Calretinin
Know about Mesothelioma and Calretinin

Statistical Validation Publication: Statistical validation for malignant pleural mesothelioma
Malignant Pleural Mesothelioma - Statistical Validation

Mesothelioma National Institute Health Publication The National Institute of Health Mesothelioma Research Publications
Mesothelioma Publications from the National Institute of Health